Indirect Treatment Comparison of Venetoclax plus Rituximab with B-cell Receptor Inhibitors in Patients with Relapsed/Refractory Chronic Lymphocytic Leukaemia

被引：0
|
作者：
Mato, A. [1 ]
Follows, G. [2 ]
Sail, K. [3 ]
Diakite, I. [4 ]
Nicoloso, D. [4 ]
Dietz, B. [5 ]
Maher, J. [6 ]
Alexiou, D. [6 ]
Chirikov, V. [4 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Dept Haematol, Cambridge, England
[3] AbbVie Inc, N Chicago, IL USA
[4] Pharmerit Int, Bethesda, MD USA
[5] AbbVie Deutschland GmbH & Ko KG, Ludwigshafen, Germany
[6] AbbVie, N Chicago, IL USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 185卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH19-PO-0
引用
收藏
页码：91 / 92
页数：2
相关论文
共 50 条
  • [31] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
    Murayama, Kayoko
    Kiguchi, Toru
    Izutsu, Koji
    Kameoka, Yoshihiro
    Hidaka, Michihiro
    Kato, Harumi
    Rai, Shinya
    Kuroda, Junya
    Ishizawa, Kenichi
    Ichikawa, Satoshi
    Ando, Kiyoshi
    Ogura, Michinori
    Fukushima, Koji
    Terui, Yasuhito
    ANNALS OF HEMATOLOGY, 2022, 101 (05) : 979 - 989
  • [32] Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies
    Kittai, Adam S.
    Best, Scott
    Thurlow, Bria
    Lam, Vi
    Hashiguchi, Taylor
    Goodyear, Shaun
    Persky, Daniel O.
    Okada, Craig
    Park, Byung
    Spurgeon, Stephen E.
    Danilov, Alexey V.
    HAEMATOLOGICA, 2021, 106 (07) : 2022 - 2025
  • [33] Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
    Handunnetti, Sasanka
    Anderson, Mary Ann
    Roberts, Andrew W.
    Davids, Matthew S.
    Ma, Shuo
    Boyer, Michelle
    Arzt, Jennifer
    Al Masud, Abdullah
    Popovic, Relja
    Jacobson, Amanda
    Kim, Su Y.
    Seymour, John F.
    EJHAEM, 2021, 2 (02): : 266 - 271
  • [34] Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
    Hillmen, Peter
    Rawstron, Andy C.
    Brock, Kristian
    Munoz-Vicente, Samuel
    Yates, Francesca J.
    Bishop, Rebecca
    Boucher, Rebecca
    MacDonald, Donald
    Fegan, Christopher
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John G.
    Patten, Piers E. M.
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher P.
    Forconi, Francesco
    Munir, Talha
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) : 2722 - +
  • [35] The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia
    Packham, Graham
    Stevenson, Freda
    SEMINARS IN CANCER BIOLOGY, 2010, 20 (06) : 391 - 399
  • [36] Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor
    Wierda, William G.
    Byrd, John C.
    Davids, Matthew S.
    Furman, Richard R.
    Cheson, Bruce D.
    Barr, Paul M.
    Eradat, Herbert
    Heffner, Leonard
    Zhou, Lang
    Verdugo, Maria
    Potluri, Jalaja
    Choi, Michael
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (05) : 961 - 966
  • [37] Venetoclax is an option in B-cell prolymphocytic leukaemia following progression on B-cell receptor pathway inhibitors
    Patil, Nikila
    Went, Richard G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (04) : E80 - E82
  • [38] Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia
    Castagna, L
    Sarina, B
    Santoro, A
    BLOOD, 2003, 102 (06) : 2309 - 2309
  • [39] Venetoclax (VEN) Is Active in Chronic Lymphocytic Leukemia (CLL) Relapsed or Refractory to More Than One B-Cell Receptor Pathway Inhibitor (BCRi)
    Wierda, William G.
    Davids, Matthew S.
    Furman, Richard R.
    Cheson, Bruce D.
    Barr, Paul M.
    Eradat, Herbert
    Heffner, Leonard
    Jones, Jeffrey
    Zhou, Lang
    Verdugo, Maria
    Humerickhouse, Rod A.
    Potluri, Jalaja
    Choi, Michael
    BLOOD, 2017, 130
  • [40] Treatment for relapsed or refractory chronic lymphocytic leukaemia: an ongoing challenge
    Strati, Paolo
    LANCET HAEMATOLOGY, 2017, 4 (03): : E97 - E98
12345